Category: Blog

Featured

NIA Reports Senolytics Show Potential to Protect Against Coronavirus in Older Mice

The NIA reports: “Cellular senescence, an aging mechanism in which cells lose normal function, may contribute to a worse response in human cells to COVID-19 and in older mice to a similar coronavirus — but a class of drug known as senolytics decreased adverse responses and increased survival for the mice. The preclinical findings from a study funded in part by NIA were recently published in Science.”

This is also the focus of one of SRF’s projects that is working on selectively removing senescent cells and reversing the damage caused by them to rejuvenate the immune system.

Read More »
Featured

SENS Research Foundation wishes you Happy International Longevity Day and Longevity Month!

The United Nations General Assembly voted to establish October 1st as the ‘International Day of Older Persons’ as recorded in Resolution 45/106. The holiday was observed for the first time on October 1st, 1991.

Following this tradition, longevity research activists from around the world call this day and the month of October; International Longevity Day and International Longevity Month.

Read More »
Featured

Annual Mitochondrial Disease Awareness Week 2021

SENS Research Foundation joins the Mitochondrial Medicine Society and MITOAction.org during the third week of September in raising awareness for the Annual Mitochondrial Disease Awareness Week.

Mitochondrial function declines with age, and these dysfunctional mitochondria adversely contribute to several metabolic and neuromuscular diseases. The mitoSENS team is working tirelessly to help discover the science to reverse and/or prevent damage to mitochondrial DNA. 

Read More »
Blog

Hyperbolic Hyperbaric “Age Reversal”

Lower-quality, clickbait-hungry media outlets love sensationalist claims, but one does expect better from the public relations department of an internationally-respected research university. And it was an easy jump from the already-overstated “In First, Aging Stopped in Humans” and “treatments can reverse two processes associated with aging and its illnesses” to saying that a treatment “can reverse

Read More »
Featured

Altos Labs recruits star researchers for rejuvenation therapeutics

As reported in the MIT Technology Review, the rejuvenation start-up is recruiting top researchers to work on “unfettered blue-sky research on how cells age and how to reverse that process.” Milner, a billionaire investor and science enthusiast, and Amazon founder Jeff Bezos are said to be investing in the venture that has so far brought on Juan Carlos Izpisúa Belmonte from the Salk Institute, UCLA professor Steve Horvath, and Nobel Prize winning scientist Shinya Yamanaka, who will chair the scientific advisory board.

Read More »

Senotherapeutics Report

With sponsorship from SRF, Longevity.Technology’s Market Intelligence Unit has published a report examining the potential of targeting cell senescence to treat many major diseases – particularly including current and upcoming investment opportunities – accompanied by a foreword written by SRF Chief Science Officer, Dr. Aubrey de Grey.

Read More »

Bold Leaps Forward for α-Synuclein Immunotherapy

α-synuclein (AS) neuropathology is one of the key forms of aging damage driving Parkinson’s disease (PD) and aspects of the “normal” loss of cognitive and autonomic nervous control with age. Immunotherapy targeting the clearance of AS aggregates from aging neurons is a key rejuvenation biotechnology for the prevention and reversal of brain aging and PD. The first human clinical trial of an AS-clearing active vaccine in early-stage PD patients was initiated in the summer of 2013. The highly promising results of this first trial have now been announced, and have led to a followup study and the launch of an EU consortium to test it for additional AS-related indications. Contemporaneously, two human trials have been initiated using a second AS-clearing rejuvenation immunotherapy, this one using infused monoclonal antibodies as a passive immunotherapic rather than an antigen-based vaccine. We review progress in this area and its links to the wider progress in PD-related rejuvenation biotechnology.

Read More »

Rejuvenation Biotechnology: Toward the Indefinite Postponement of Menopause

A recent interview with SENS Research Foundation Chief Science Officer Dr. Aubrey De Grey evoked an eruption of worldwide media coverage, because of a brief comment he made to the effect that rejuvenation biotechnology could eliminate menopause within twenty years. This post gives some examples of foreseeable biotechnologies carrying us toward that eventuality.

Read More »

The Neuroprotector’s Dilemma: A Potential Neuroprotective Agent with a Janus Face

Rejuvenation of the aging brain will require the integrated application of several core rejuvenation biotechnologies, including notably those that remove intra- and extraneuronal aggregates implicated in neurodegenerative aging and mature cell therapy. Numerous aggregate-clearing rejuvenation biotechnologies are now in human trials, whereas mature cell therapy for the brain is a more challenging goal and will not be available for some time. In this context, an alternative approach to maintaining the viability of aging neurons could complement aggregate-clearing therapies to preserve neurons until neural replacement and reinforcement matures. In this post we explore the potential of one recently-emerged approach: inhibition of the unfolded protein response (UPR).

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: